Print
23 May 2018
GMP News
The Ministry of Industry and Trade of Russia confirmed that the industrial biotechnology cluster of the Kirov region and its specialized organization “The Association of Industrial Biotechnology Cluster” comply with the requirements approved by the Decree of the Russian Government No. 779, dated July 31, 2016.
The companies that are the cluster members want to implement several joint projects having total investments of more than 700 million rubles.
The industrial cluster became the first in the region to have been included in the list of industrial clusters and specialized organizations of industrial clusters of the Ministry of Industry and Trade of Russia.
The cluster brings together leading biotech and pharmaceutical companies of the region to develop and produce the medicinal products that are highly sought after in the market. It has 11 members, including such manufacturers as Nanolek LLC, AVVA RUS JSC, AgroVet LLC, Kirov Pharmaceutical Factory LLC, Rosplasma Medical Scientific and Production Center, SKB MT LLC, and others. The cluster also includes two educational institutions (Vyatka State University and Kirov State Medical University of the Ministry of Health of Russia) and four enterprises to manufacture components, equipment, and packaging for finished medicinal products.
The first application for co-financing of the joint project involving Nanolek and other participants of the cluster is expected to be submitted to the Russian Ministry of Industry and Trade as early as in 2018. This project is aimed at organizing the industrial manufacturing of recombinant flu vaccine. According to the plans, about 100 million rubles of federal funds will be raised for its implementation.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.